Microsulis Medical Limited Receives FDA Clearance for Upgraded Microwave Ablation Device
12/17/2012 8:58:17 AM
Microsulis Medical Ltd, the medical device company specialising in minimally invasive, microwave ablation technology for the coagulation of soft tissue, has received FDA clearance for its upgraded Accu2i pMTA applicator. The initial version of the single, high-power, high-frequency 2.45GHz saline-cooled needle was cleared for use in the US as part of the Acculis MTA system in 2010. Following two years of global distribution, and in response to customer feedback and growing product demand, Microsulis has updated the device's design and manufacturing process. Improvements include a refined optically clear moulded handle and improved connection cartridge. Clinicians will continue to get the same results from Mark 2 of this market leading, minimally invasive product, while benefiting from improvements in the look and feel of the device. The changes also allow Microsulis to scale-up production output to satisfy its expanding customer base. Stuart McIntyre, CEO of Microsulis Medical Ltd, said: "2.45GHz microwave ablation is becoming the new global standard for volume tissue coagulation, giving clinicians options for patients that were not possible with radiofrequency ablation technology. "To keep up with demand and fuel the growth of this technology, it was necessary to introduce production and design solutions to allow large volume, scalable, high-quality manufacturing. Hence we have introduced a new improved design that has now received marketing clearance from the US Food and Drug Administration. "The product continues to be available for global distribution and, with this clearance, we look forward to offering this new applicator to our many US based customers."
comments powered by